CA2048619A1 - Utilisation de proteines bactericides accroissant la permeabilite ou de leurs analogues actifs biologiquement pour traiter des infections a germes gram-negatifs associees aux lipopolysaccharides - Google Patents

Utilisation de proteines bactericides accroissant la permeabilite ou de leurs analogues actifs biologiquement pour traiter des infections a germes gram-negatifs associees aux lipopolysaccharides

Info

Publication number
CA2048619A1
CA2048619A1 CA2048619A CA2048619A CA2048619A1 CA 2048619 A1 CA2048619 A1 CA 2048619A1 CA 2048619 A CA2048619 A CA 2048619A CA 2048619 A CA2048619 A CA 2048619A CA 2048619 A1 CA2048619 A1 CA 2048619A1
Authority
CA
Canada
Prior art keywords
bactericidal
treat
biologically active
increasing protein
gram negative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2048619A
Other languages
English (en)
Other versions
CA2048619C (fr
Inventor
Marian N. Marra
Randal W. Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002323630A priority Critical patent/CA2323630A1/fr
Publication of CA2048619A1 publication Critical patent/CA2048619A1/fr
Application granted granted Critical
Publication of CA2048619C publication Critical patent/CA2048619C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA002048619A 1989-02-14 1990-02-14 Utilisation de proteines bactericides accroissant la permeabilite ou de leurs analogues actifs biologiquement pour traiter des infections a germes gram-negatifs associees aux lipopolysaccharides Expired - Fee Related CA2048619C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002323630A CA2323630A1 (fr) 1989-02-14 1990-02-14 Utilisation de proteines bactericides accroissant la permeabilite ou de leurs analogues actifs biologiquement pour traiter des infections a germ es gram-negatifs associees aux lipopolysaccharides

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31084289A 1989-02-14 1989-02-14
US310,842 1989-02-14
US468,696 1990-01-22
US07/468,696 US5089274A (en) 1989-02-14 1990-01-22 Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
PCT/US1990/000837 WO1990009183A1 (fr) 1989-02-14 1990-02-14 Utilisation d'une proteine bactericide/accroissant la permeabilite ou d'analogues biologiquement actifs de cette proteine pour traiter la lipopolysaccharide associee aux infections gram negatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002323630A Division CA2323630A1 (fr) 1989-02-14 1990-02-14 Utilisation de proteines bactericides accroissant la permeabilite ou de leurs analogues actifs biologiquement pour traiter des infections a germ es gram-negatifs associees aux lipopolysaccharides

Publications (2)

Publication Number Publication Date
CA2048619A1 true CA2048619A1 (fr) 1990-08-15
CA2048619C CA2048619C (fr) 2001-02-13

Family

ID=26977616

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002048619A Expired - Fee Related CA2048619C (fr) 1989-02-14 1990-02-14 Utilisation de proteines bactericides accroissant la permeabilite ou de leurs analogues actifs biologiquement pour traiter des infections a germes gram-negatifs associees aux lipopolysaccharides

Country Status (11)

Country Link
US (1) US5089274A (fr)
EP (3) EP1384485A1 (fr)
JP (1) JP2966923B2 (fr)
KR (1) KR0160133B1 (fr)
AT (2) ATE246933T1 (fr)
AU (1) AU647734B2 (fr)
CA (1) CA2048619C (fr)
DE (2) DE69034096T2 (fr)
ES (2) ES2205111T3 (fr)
IL (1) IL93360A (fr)
WO (1) WO1990009183A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132775A (en) * 1987-08-11 2000-10-17 New York University Therapeutic uses of biologically active bactericidal/permeability-increasing protein fragments
EP0652230B1 (fr) * 1987-08-11 2005-12-14 New York University Fragments biologiquement actifs de protéine bactéricide/accroisant la perméabilité
US5576292A (en) * 1987-08-11 1996-11-19 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5594113A (en) * 1988-06-23 1997-01-14 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
US6265187B1 (en) 1989-02-14 2001-07-24 Incyte Pharmaceuticals, Inc. Recombinant endotoxin-neutralizing proteins
US6093801A (en) * 1989-02-14 2000-07-25 Incyte Pharmaceuticals, Inc. Recombinant analogs of bactericidal/permeability increasing protein
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5171739A (en) 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5484885A (en) * 1989-07-05 1996-01-16 Emory University Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
US5489676A (en) * 1990-03-30 1996-02-06 Elsbach; Peter Polypeptides that potentiate bactericidal/permeability-increasing protein and methods for treating bacterial infections
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
EP0563222B1 (fr) * 1990-12-03 1998-02-25 New York University Fragments biologiquement actifs de proteines bactericides/accroissant la permeabilite
WO1992020715A1 (fr) * 1991-05-16 1992-11-26 Associates Of Cape Cod, Inc. Proteine de liaison et de neutralisation d'endotoxine et ses utilisations
WO1993006228A1 (fr) * 1991-09-26 1993-04-01 Incyte Pharmaceuticals, Inc. Nouvelle forme de proteine fixatrice des liposaccharides
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性／浸透性増大タンパク質（Ｂａｃｔｅｒｉｃｉｄａｌ／Ｐｅｒｍｅａｂｉｌｉｔｙ Ｉｎｃｒｅａｓｉｎｇ ｐｒｏｔｅｉｎ：ＢＰＩ）及び界面活性剤を含有する医薬組成物
JPH08509703A (ja) * 1993-03-12 1996-10-15 ゾーマ コーポレイション 殺菌／透過性増加タンパク質産物の治療用途
US6214789B1 (en) * 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
EP0760849A1 (fr) * 1993-04-30 1997-03-12 Incyte Pharmaceuticals, Inc. Proteines de recombinaison de type augmentant la permeabilite bactericide (bpi) et de type fixant le liposaccharide (lbd), molecules codant pour ces proteines, leurs procedes de production et leurs utilisations
WO1995000641A1 (fr) * 1993-06-17 1995-01-05 Xoma Corporation Derives de la proteine de liaison du lipopolysaccharide
WO1995002414A1 (fr) * 1993-07-14 1995-01-26 Xoma Corporation Methode permettant de potentialiser l'activite bactericide d'un produit contenant la proteine bpi par l'administration de produits contenant la proteine lbp
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
PT759774E (pt) * 1993-09-22 2002-11-29 Xoma Technology Ltd Metodo para o tratamento de infeccoes bacterianas gram-negativas por administracao de um produto de proteina bactericida indutora da permeabilidade (bip) e de um antibiotico
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
US6686332B1 (en) * 1993-10-15 2004-02-03 Xoma Corporation Method of treating depressed reticuloendothelial system function
MX9602570A (es) * 1994-01-14 1997-04-30 Xoma Corp Metodos y materiales anti-fungosos.
ATE219684T1 (de) * 1994-01-14 2002-07-15 Xoma Technology Ltd Anti gram positive bakterielle verfahren und mittel
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5830860A (en) * 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
DE69530689T2 (de) * 1994-04-21 2004-03-25 Leukotech A/S Heparin-binding protein zur behandlung von sepsis
US5578568A (en) 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
US5532216A (en) * 1994-06-24 1996-07-02 Incyte Pharmaceuticals, Inc. Neutralization of non-lipopolysaccharide compounds by bactericidal/permeability-increasing protein
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
US5610075A (en) * 1995-01-17 1997-03-11 Stahl-Rees; Marianne Competitive electrochemiluminescence assays for endotoxins using a ruthenium label
US5939390A (en) * 1995-03-09 1999-08-17 Novo Nordisk A/S Pharmaceutical composition
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
WO1997004008A1 (fr) * 1995-07-20 1997-02-06 Xoma Corporation Peptides antifongiques
DE69703689T2 (de) 1996-05-10 2001-05-10 Xoma Technology Ltd., Berkeley Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
NZ332954A (en) * 1996-05-23 2000-07-28 Xoma Corp Use of BPI protein products to treat humans with hemorrhage due to trauma
CA2255865C (fr) * 1996-05-24 2008-10-14 The Regents Of The University Of Minnesota Synthese de peptides formant des feuillets beta solubles
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) * 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
CN1324244A (zh) * 1998-10-22 2001-11-28 伊莱利利公司 治疗脓毒症的方法
AU2003211163A1 (en) 2002-02-20 2003-09-09 Regents Of The University Of Minnesota Partial peptide mimetics and methods
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
MX392701B (es) * 2016-05-27 2025-03-24 Exoxemis Inc Composiciones de mieloperoxidasa y métodos para la inhibición de lipopolisacáridos y lípido a.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006279A1 (fr) * 1985-04-30 1986-11-06 Scripps Clinic And Research Foundation Proteine de phase aigue modulant l'activite endotoxique de lipopolysaccharides, compositions et procedes
EP0487517A1 (fr) * 1986-10-07 1992-06-03 Mainframe Data Limited Appareil et procede destine a eviter la transmission de maladies
US5126257A (en) * 1986-11-26 1992-06-30 Cornell Research Foundation Antimicrobial proteins, compositions containing same and uses thereof
EP0652230B1 (fr) * 1987-08-11 2005-12-14 New York University Fragments biologiquement actifs de protéine bactéricide/accroisant la perméabilité
GB8815978D0 (en) * 1988-07-05 1988-08-10 British Telecomm Method & apparatus for encoding decoding & transmitting data in compressed form

Also Published As

Publication number Publication date
CA2048619C (fr) 2001-02-13
EP0841064A1 (fr) 1998-05-13
DE69034096D1 (de) 2003-09-18
IL93360A (en) 1997-04-15
ES2122958T3 (es) 1999-01-01
DE69032579T2 (de) 1999-02-11
WO1990009183A1 (fr) 1990-08-23
AU647734B2 (en) 1994-03-31
US5089274A (en) 1992-02-18
EP0460058B1 (fr) 1998-08-19
DE69032579D1 (de) 1998-09-24
EP0841064B1 (fr) 2003-08-13
EP0460058A1 (fr) 1991-12-11
JP2966923B2 (ja) 1999-10-25
KR0160133B1 (en) 1998-12-01
JPH04506510A (ja) 1992-11-12
EP1384485A1 (fr) 2004-01-28
AU5170690A (en) 1990-09-05
DE69034096T2 (de) 2004-06-17
ATE169820T1 (de) 1998-09-15
ES2205111T3 (es) 2004-05-01
ATE246933T1 (de) 2003-08-15
EP0460058A4 (en) 1992-02-12

Similar Documents

Publication Publication Date Title
CA2048619A1 (fr) Utilisation de proteines bactericides accroissant la permeabilite ou de leurs analogues actifs biologiquement pour traiter des infections a germes gram-negatifs associees aux lipopolysaccharides
DE69019009D1 (de) Zellkulturverfahren.
DE69021435D1 (de) Ionen-Implantationsgerät.
CA2020439A1 (fr) Proteine modifiee biologiquement active
DE69007709D1 (de) Stapelverdampfer.
FI872747A7 (fi) Arrangemang foer renhaollning av de inre ytorna i en ullkammare foer mineralullstillverkning.
NO885751D0 (no) Bakteriestammer.
DE69017075D1 (de) Ionen-Implantationsgerät.
NL194908B (nl) Medicinaal preparaat voor de behandeling van verworven immuundeficientie-syndroom (AIDS) op basis van een celsuspensie met hemopoetische stamcellen.
IT8721896A0 (it) Piccola elettrovalvola inviolabile.
AU7650687A (en) Particulate hydroperoxidized poly-N-vinyl lactam, its preparation and use thereof
FI874126L (fi) Anaerobt foerfarande.
DE3773696D1 (de) Magnetventilanordnungen.
IT1280883B1 (it) Elettrodo per l'acquisizione di un segnale biologico di natura elettrica, in particolare un segnale elettrocardiografico.
IT8722167A0 (it) Struttura di valvola cardiaca artificiale ad elevato rendimento.
FR2655124B1 (fr) Valve de chargement d'accumulateur.
AU2740788A (en) Inverted drawn cup bearing
FI893548L (fi) Bacillus-celler.
FR2596488B1 (fr) Clapet de vidange de citerne, notamment de citerne calorifugee
DE69000402D1 (de) Elektrochemische bearbeitung.
DE3782199D1 (de) Biologisch aktive peptide tan-866.
WO1997025421A3 (fr) PROTEINE INDUITE PAR LE DEPRENYL$m(3)
FR2635639B1 (fr) Procede d'humidification des terres
CA2003794A1 (fr) Expression de proteines de vih dans des cellules de drosophiles
ES1010178Y (es) Valvula reguladora de vacio.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed